ViGeneron Announces FDA Clearance of IND for Novel mRNA Trans-Splicing Gene Therapy VG801 to Treat Stargardt Disease and Other ABCA4-Linked Retinal Dystrophies
December 18, 2024 08:00 ET
|
ViGeneron GmbH
VG801 is the first FDA IND clearance for novel mRNA trans-splicing gene therapy, delivering the full-length functional ABCA4 gene to target the genetic root cause of retinal dystrophies associated...
Muscular Dystrophy Association and Coalition to Cure Calpain 3 Partner to Fund $300,000 Research Grant for Gene Therapy Development in Limb-Girdle Muscular Dystrophy
December 17, 2024 08:54 ET
|
Muscular Dystrophy Association
New York, Dec. 17, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) and Coalition to Cure Calpain 3 (C3) announced today collaborative funding of a $300,000 research grant to...
Growth Trends in the CRISPR and Cas Gene Market: Industry Opportunities and Strategies to 2028 & 2033
December 13, 2024 09:27 ET
|
Research and Markets
Dublin, Dec. 13, 2024 (GLOBE NEWSWIRE) -- The "CRISPR and Cas Gene Market Opportunities and Strategies to 2033" report has been added to ResearchAndMarkets.com's offering.This report describes and...
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
December 11, 2024 07:02 ET
|
Ocugen
MALVERN, Pa., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2024
December 10, 2024 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Ori Biotech and Fresenius Kabi Collaborate to Advance Modular, Scalable Manufacturing of Cell and Gene Therapies
December 10, 2024 08:31 ET
|
Ori Biotech Ltd
Ori Biotech and Fresenius Kabi partner to integrate Ori’s IRO® Platform with Cue® and Lovo® systems, advancing scalable cell and gene therapy manufacturing
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
December 10, 2024 07:05 ET
|
uniQure Inc.
~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License...
COVID Vaccines’ Genetic Mechanism Inadequately Tested, according to Journal of American Physicians and Surgeons (AAPS)
December 09, 2024 10:22 ET
|
Association of American Physicians and Surgeons
Pfizer's COVID mRNA products are regulated as vaccines, not as gene therapy, unlike comparable anti-cancer products, Safety studies are thus inadequate.
Amarna Therapeutics Partners with NorthX Biologics to Advance Nimvec™ AM510 Gene Therapy Development
December 03, 2024 16:10 ET
|
Amarna Therapeutics
Amarna Therapeutics Partners with NorthX Biologics to Advance Nimvec™ AM510 Gene Therapy Development Leiden, The Netherlands, 3 December 2024 - Amarna Therapeutics, (“Amarna” or “the Company”), a...
Oligonucleotides Market Outlook 2034: Projected to Reach US$ 13.1 Billion by 2034, Driven by Expanding Applications in Biotechnology and Precision Medicine | TMR
December 02, 2024 10:08 ET
|
Transparency Market Research
Wilmington, Delaware, Transparency Market Research Inc.:, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The global oligonucleotides market (mercado de oligonucleótidos) is poised for significant growth,...